Here’s whether Terns Pharmaceuticals, Inc. Common Stock (TERN) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+8.10% over 10 days); RSI 36 — healthy momentum range; strong 1-year return of +2250.4%; 3-month momentum positive (+43.9%). Currently 1.0% off its 52-week high. Score: +7/7.
TERN is in a confirmed uptrend, trading above both its 50-day ($46.00) and 200-day ($25.11) moving averages. An RSI of 35.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +2250.4% compares to +35.1% for SPY (beat the market by 2215.4%).
$10,000 invested 1 year ago→ $235,045 today
vs. S&P 500 (SPY) — same period beat market by 2215.4%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($25.11)
✓Above 50-day MA ($46.00)
✓RSI(14) neutral zone (30–70) — currently 35.8
✓Positive return (+2250.4%)
✓Within 10% of period high (−1.0%)
Period Range $52.65
$2.22$53.19
RSI (14) 35.8
0 · OversoldOverbought · 100
Key Metrics
Price$52.65
Period Return+2250.4%
Period High$53.19
Period Low$2.22
Drawdown−1.0%
MA-50$46.00
MA-200$25.11
RSI (14)35.8
Avg Volume (30d)9.2M
vs. SPYbeat by 2215.4%
Return Rank#1 of 996
Trend Signals
Price is above the 200-day moving average ($25.11)